Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001708269-25-000004·Atlas Venture Fund XI, L.P.
Schedule 13D ownership disclosure
Sionna Therapeutics Inc
Common Stock · CUSIP: 829401108
Event date: 2025-10-16
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Atlas Venture Fund XI, L.P.Reported CIK 0001708269
Shares: 2,382,495.00 · Class: 5.4%
- Atlas Venture Associates XI, L.P.Reported CIK 0001780068
Shares: 2,382,495.00 · Class: 5.4%
- Atlas Venture Associates XI, LLCReported CIK 0001780067
Shares: 2,382,495.00 · Class: 5.4%
- Atlas Venture Opportunity Fund II, L.P.Reported CIK 0001885327
Shares: 701,985.00 · Class: 1.6%
- Atlas Venture Associates Opportunity II, LPReported CIK 0001935814
Shares: 701,985.00 · Class: 1.6%
- Atlas Venture Associates Opportunity II, LLCReported CIK 0001935810
Shares: 701,985.00 · Class: 1.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001708269-25-000004
- Form type
- SCHEDULE 13D/A
- Filer
- Atlas Venture Fund XI, L.P.
- CIK
- CIK 1708269
- Filed
- Oct 20, 2025
- Reporting period
- Oct 16, 2025
- Description
- Schedule 13D beneficial ownership